The National Cancer Institute periodically highlights a particular trial or group of trials out of more than 150 available cancer clinical trials conducted at the National Institutes of Health in Bethesda, Maryland.
Clinical Trial Spotlights for a variety of different cancer topics include:
Clinical Trials—Dr. Howard A. Fine
- A Phase II Trial of Enzastaurin (LY317615) in Combination With Bevacizumab in Adults With Recurrent Malignant Gliomas
NCI-08-C-0015 - A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
NCI-07-C-0053 - A Phase II Study of O6-benzylguanine (O6-BG) and Temozolomide in Patients With Glioblastoma Progressing at Least 3 Months After Completion of Primary Treatment With Radiation Therapy and Temozolomide
NCI-07-C-0052 - A Phase II Trial of Tamoxifen and Bortezomib in Patients With Recurrent High-Grade Gliomas
NCI-05-C-0137
Clinical Trial—Dr. Katherine E. Warren
- Phase II Study of Pegylated Interferon Alfa-2b (PEF-Intron) in Children With Diffuse Pontine Gliomas
NCI-02-C-0193
Clinical Trials—Dr. James Gulley
- A Double-Blind Randomized Phase 2.5 Trial of ONY-P1 Vaccine Versus Placebo in Men With D0 Prostate Cancer Following Limited Androgen Ablation
NCI-07-C-0188 - A Randomized Phase 2.5 Study of 153Sm-EDTMP (Quadramet) With or Without a PSA TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer
NCI-07-C-0106
Clinical Trials—Dr. Phillip Arlen
- A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutine Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer
NCI-07-C-0107 - A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in Patients With Metastatic Breast Cancer
NCI-05-C-0229
Clinical Trial—Dr. Claude Sportés
- A Phase I/II Study of Tumor Vaccine Following Chemotherapy in Patients With Previously Untreated Metastatic Breast Cancer: Vaccine-Induced Bias of T-Cell Repertoire Reconstitution After T-Cell Re-Infusion
NCI-03-C-0040
Clinical Trial—Dr. John Morris
- A Phase I/II Study of an Antitumor Vaccination Using Alpha (1.3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer
NCI-04-C-0049
Clinical Trial—Dr. Robert Yarchoan
- A Pilot Study to Investigate the Safety and Immunogenicity of a Peptide Vaccine for HIV Infected HLA-A2 Individuals Designed to Impede the Development of Antiretroviral Resistance
NCI-06-C-0211
Clinical Trial—Dr. Steven Rosenberg
- Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes
NCI-07-C-0175
Clinical Trial—Dr. Michael Bishop
- Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders
NCI-07-C-0195 - Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes
NCI-07-C-0064
To search all clinical trial summaries, click here
To view archived list of Clinical Trial Spotlights, click here
Back to Top
